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a b s t r a c t 
Background: To fully realize efficacy in cancer screening, timely and appropriate treatment for partic- 
ipants with malignant lesions is critical. However, the health-seeking behavior of patients with upper 
gastrointestinal (G.I.) cancer identified in population-level screening programs in China is unknown. 
Methods: A community-based real-world investigation was conducted with 136 upper G.I. cancer patients 
detected in a large screening cohort in an area of high-risk for upper G.I. cancer in China. Using local 
medical claims data and semi-structured face-to-face interview, we collected information regarding the 
clinical treatment regimen and factors which result in the lack of timely and appropriate treatment. 
Findings: The treatment records for 133 upper G.I. cancer patients were acquired. Among these, 48 
(36 • 09%) patients did not receive treatment within three months of initial diagnosis, and treatment of 
early-stage cancer was more likely to be delayed. Sixteen patients did not seek further diagnostic testing 
due to their low health-awareness and socio-economic status. Another 20 participants proactively sought 
further diagnostic evaluation in health care facilities but were prevented from receiving further treatment 
due to low sensitivity of given diagnostic test(s), failure to recognize the significance of screening results, 
and/or lack of basic knowledge of diagnosis and treatment for early cancer on the part of clinicians. The 
treatment regimen offered to patients depended largely on the level of health care facilities they visited, 
and non-medical factors were the main reasons for choice of health care facilities. 
Interpretation: A coordinated, system-based management strategy is urgently needed to support the de- 
sign of upper G.I. cancer screening programs in rural populations in China. 
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Research in context 
Evidence before this study 
Achieving efficacy of screening relies largely on timely ap- 
propriate treatment for participants following detection of 
malignant lesions. Effective management of screening pos- 
itive individuals is thus an important component of any 
screening program. We searched PubMed and Google Scholar 
for studies published from the inception of the database to 
Jan 1, 2021, with no language restrictions. Using the search 
terms “cancer screening program” or “cancer screening trial”
or “cancer screening projects”, mass cancer screening pro- 
grams were found with this specific combination. In these 
mass cancer screening projects in different countries we 
identified, roughly two management strategies were adopted 
including “screening & recommendation” and “screening & 
treatment”. A series of early diagnosis and early treatment 
projects for upper G.I. cancer had been launched in high- 
incidence rural areas of China in the past decades. In these 
projects, “screening & recommendation” strategy was widely 
adopted for management of screening positive individuals. 
However, whether these screening-detected cancer patients 
received timely and appropriate treatment is unknown, and 
what factors influenced their health-seeking behavior had not 
been well determined. 
Added value of this study 
To our knowledge, this is the first study to investigate the 
real-world health-seeking behavior of screening-detected up- 
per G.I. cancer patients in a rural area with high incidence 
for esophageal cancer in China. We mapped out the health- 
seeking trajectory of screening-detected upper G.I. cancer pa- 
tients, revealed the reasons for lack of timely treatment and 
for choice of health facilities for treatment. 
Implications of all the available evidence 
We recommend adoption of a coordinated, system-based 
management strategy when designing an upper G.I. cancer 
screening project in rural populations in China. Our find- 
ings provide important evidence for formulating and tailoring 
management strategy for cancer screening in rural areas in 
China, and also provide guidance for screening in other simi- 
lar settings. 
ntroduction 
Cancer is the leading cause of death worldwide, and is an im- 
ortant barrier to increasing life expectancy in the 21st century. 1 
he development of cancer is a multi-step process, and a wide va- 
iety of cancers are amenable to early detection resulting in earlier 
iagnosis, thus improving prognosis. Screening has therefore been 
idely accepted as an optimal secondary prevention strategy for 
ancers, especially for those cancers with etiologic factors which 
ave not been definitively identified. 2 
Achieving efficacy in screening is dependent largely on timely 
nd appropriate treatment for participants with malignant lesions 
hich have been detected in screening. 3 It is therefore crucial 
o formulate a management strategy which ensures participants 
n screening programs with screening-detected abnormalities re- 
eive timely and appropriate clinical treatment consistent with 
ocal health system capacity and socio-economic level. Currently, 
anagement strategies for persons in cancer screening programs 
ho are screening-positive can roughly be classified into two types 
hich include “screening & recommendation” and “screening & 2 reatment”. The former has been the most widely adopted strategy. 
aking the Prostate, Lung, Colorectal and Ovarian Cancer Screen- 
ng Trial 3 and the National Lung Screening Trial 4 as examples, it 
s noteworthy that these cancer screening programs ceased after 
creening, together with communication of findings, and referral, 
nd the patients were then free to choose whether to seek fur- 
her diagnosis and treatment or not. The less commonly employed 
screening & treatment” strategy, which was adopted in an endo- 
copic screening trial in China 5 and in a colorectal screening trial 
n Norway, 6 directly provided diagnostic testing and therapeutic 
rocedures for individuals who were screening-positive. 
China has a high incidence of esophageal cancer (EC), and most 
igh-risk regions in China are rural areas where people have rela- 
ively low socio-economic status and limited access to health ser- 
ices. 7 The central government of China has implemented a se- 
ies of early diagnosis and early treatment projects for upper gas- 
rointestinal (G.I.) cancer in high-incidence rural areas beginning 
n 2005, and most of these programs have adopted the “screening 
 recommendation” strategy. A total of 2 • 16 million people under- 
ent upper G.I. cancer screening up to 2018, and among these in- 
ividuals over 34 thousand were found to have upper G.I. cancer; 
0% of these individuals were diagnosed at early stage. 8 Given the 
ack of a strict referral mechanism in China’s health system, 9 these 
creening-detected patients were often left to decide for them- 
elves whether, and at which health care facility to seek further di- 
gnosis and treatment. Such decisions are strongly affected by in- 
ividual health literacy, socio-economic status and health system- 
elated factors such as health care availability and accessibility. 10 
owever, to date no study has reported on the performance of 
he “screening & recommendation” strategy in China. Therefore, 
apping out the health-seeking trajectory of individuals who are 
creening-positive together with the factors associated with their 
ealth-seeking behavior is a matter of importance. Such informa- 
ion has potential to inform planning of cancer screening in China 
n the future. 
In this study, for the first time we conducted a community- 
ased mixed methods study based on the Endoscopic Screening for 
sophageal Cancer in China (ESECC) trial, which was a population- 
ased randomized controlled trial in a region that is high-risk for 
C in China. 11 , 12 This study aimed to evaluate the performance of 
he “screening & recommendation” strategy in a real-world screen- 
ng project in rural China. We investigated the health-seeking be- 
avior of participants in whom malignant lesions were detected in 
he upper digestive tract at baseline screening in the ESECC trial, 
nd interviewed these participants face-to-face to identify the rea- 
ons for lack of timely and appropriate treatment. Factors affecting 
heir decision-making in choosing health care facilities for treat- 
ent were also evaluated. 
ethods 
he parent study 
This study was based on the ESECC randomized controlled trial 
ClinicalTrials.gov: NCT01688908) and a detailed description of the 
riginal design of this trial has been reported elsewhere. 11 Briefly, 
his trial was initiated in 2012, and 668 villages were randomly 
elected from Hua county, Henan Province, China, which is a high- 
ncidence area for esophageal squamous cell carcinoma (ESCC). A 
locked randomization procedure was used to allocate these vil- 
ages into the screening arm or the control arm at a ratio of 1:1 
334 villages, ~16,0 0 0 participants aged 45-69 in each arm). In the 
creening arm, standard upper G.I. endoscopy with iodine staining 
as performed at baseline screening. A computer-aided one-on- 
ne questionnaire was completed by all participants at the baseline 
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Figure 1. Procedure for collecting data on the treatment history of 136 screening-detected upper G.I. cancer patients from the ESECC trial, rural Hua County, China. 













































database of the National Health Commission of China. nvestigation to collect information on characteristics (demograph- 
cs and potential risk factors for EC) of the participants. 
The ESECC trial adopted a “screening & recommendation” strat- 
gy to manage participants with malignant lesions detected at 
aseline screening. When participants were diagnosed with ma- 
ignant upper G.I. lesion(s), a designated endoscopist with stan- 
ardized training informed the participant, or informed their first- 
egree relatives of the results in a face-to-face communication, and 
rovided these individuals with appropriate medical advice about 
urther diagnostic testing and clinical treatment according to cur- 
ent guidelines. 
tudy participants 
Baseline endoscopic screening for the ESECC trial was com- 
leted by September 2016, and 15,299 participants in the screening 
rm underwent upper G.I. endoscopic examination. Among these 
ndividuals, 136 were found to have malignant lesions, including 
13 malignant esophageal lesions, 12 malignant lesions of the gas- 
ric cardia, and 11 malignant gastric non-cardial lesions. All of 
hese 136 participants were analyzed in this study. 
ata collection 
“Timely treatment” was defined in this study as initial cancer- 
elated clinical treatment undertaken within three months of the 
iagnosis in the baseline screening. We adopted a two-stage proce- 3 ure to collect data on the treatment history of these 136 patients 
 Figure 1 ). 
First, information regarding the clinical treatment regimen of 
he participants was collected with linkage to claims data from 
he New Rural Cooperative Medical Scheme (NCMS), which is a 
overnment-run health insurance program in rural China with cov- 
rage of nearly 100% in the study area that had previously proved 
o be a reliable data source regarding cancer diagnosis and treat- 
ent. 13-15 Detailed claims records from the NCMS for all partic- 
pants from January 2012 to September 2017 were carefully re- 
iewed to confirm whether they had received cancer-related ther- 
py, which included endoscopic therapy, radical surgery, radiother- 
py, and chemotherapy. 
Second, door-to-door investigation was conducted from Decem- 
er 2016 to May 2018, during which all study participants were 
nterviewed face-to-face with a semi-structured questionnaire. The 
reatment status of the participants without cancer-related therapy 
ecords in the NCMS was confirmed. Individuals who did not re- 
eive timely treatment were asked to describe the reasons underly- 
ng the delay, and those who received treatment were asked about 
he details of the clinical diagnosis and therapeutic process, such 
s tumor stage, date of initial treatment, the level of the health 
are facility where they were treated, the treatment regimen which 
as adopted and the factors most important to them when choos- 
ng health care facilities. The level of a given health care facility 
primary, secondary, or tertiary) is decided based on the official 
16 















































































































A telephone interview was used if the patient was not home 
uring the door-to-door interviews. If the patient had died before 
he interview, their first-degree relatives or the village doctors who 
ere responsible for the primary health care of local rural res- 
dents were interviewed. All interviews were audio-recorded and 
ranscribed. 
ata analysis 
We used a conventional analysis approach, and inductively ana- 
yzed transcripts to identify reasons for lack of timely treatment, 
nd reasons for choice of health care facilities. We developed a 
odebook, which was refined iteratively. Two authors analyzed the 
ranscripts independently and resolved disagreements through dis- 
ussion. Once all interviews were coded using NVivo 12 software 
QSR International Pty Ltd.), we summarized the reasons for a lack 
f timely treatment and for choice of health care facilities. “Early- 
tage lesions” in the stratified analysis refers to severe dysplasia 
nd carcinoma in situ; and “non-early-stage lesions” includes ESCC, 
astric cardia and gastric non-cardial adenocarcinoma. 
All variables were first evaluated with unconditional univariate 
ogistic regression analysis to identify potential factors associated 
ith lack of timely treatment. Age, gender and variables with p < 
 • 05 were subject to multivariable logistic regression analysis. Risk 
ifference was calculated for each variable, and 95% confidence in- 
ervals (CI) were estimated using the Wilson method. All statistical 
nalysis was performed using STATA version 15 • 1 (STATA, College 
tation, Texas, USA). All tests were two-sided and had a signifi- 
ance level of 0 • 05. 
thics statement 
Research protocols for the present study were approved by the 
nstitutional Review Board of the Peking University School of On- 
ology, Beijing, China (No. 2011101110). All participants provided 
nformed consent. 
ole of the funding source 
The funding sources had no role in the study design, data col- 
ection, analysis, interpretation, or writing of the report. 
esults 
Among the 136 patients with screening-detected malignant le- 
ions in the ESECC trial, treatment records for 133 (97 • 79%) were 
cquired and 114 (83 • 82%) responded to semi-structured inter- 
iews (109 face-to-face, five over the telephone). As shown in 
able 1 , 48 (36 • 09%) of the participants had not received clini-
al treatment targeting malignant upper G.I. lesion(s) within three 
onths after the initial screening, and of these individuals 47 re- 
ained untreated at the time the interview was conducted (at 
east 586 days after the baseline screening). Only one patient 
ought treatment six months after the initial screening, due to ob- 
ious symptoms. Hence, this patient was not deemed to have re- 
eived screening-related treatment. 
As shown in Table 2 , tumor stage was found to be an inde-
endent risk factor for lack of timely treatment. The proportion 
f participants who did not receive timely treatment was signif- 
cantly higher in patients with early-stage lesions than in those 
ith non-early-stage lesions [51 • 14% vs. 6 • 67%, OR:16 • 46, 95% CI
4 • 62, 58 • 62)]. This discrepancy was larger for participants with 
sophageal malignant lesions, where 53 • 95% of early-stage and 
 • 88% of non-early-stage lesions were not treated in a timely man- 
er [OR:23 • 36, 95%CI (4 • 97, 109 • 85)]. Other factors, including age,
ender, education, job type, annual per capita household income, 4 arital status, living arrangements, family history of EC and G.I. 
ancer-related symptoms, had no statistical correlation with lack 
f timely treatment (Data was not shown). 
Among the 48 participants who did not receive timely treat- 
ent, 36 participated in our face-to-face interviews. Findings of 
his qualitative analysis are presented below. 
A total of 20 participants proactively sought further diagnostic 
valuation in health care facilities after screening, but were pre- 
ented from receiving further treatment for three reasons: (1) 55% 
11/20) had an endoscopy re-examination in which no malignant 
esion was detected. (2) 25% (5/20) consulted clinicians, who told 
atients that they could be cured with oral medication or tra- 
itional Chinese medicine and did not refer the patients for en- 
oscopic re-examination. (3) 20% (4/20) consulted clinicians who 
uggested only regular surveillance. 
The other 16 participants did not seek further clinical diagnos- 
ic testing after screening for the following five principal reasons: 
1) 56 • 25% (9/16) chose to ignore the screening results and the ad- 
ice of the screening team professionals. These individuals believed 
hat they were healthy, as no symptoms were identified. (2) 18 • 75% 
3/16) were concerned about incurring financial burden, as they 
ere of low economic status and could not get sufficient support 
rom their families. (3) 12 • 50% (2/16) felt their social value was low 
nd gave up seeking further diagnosis and treatment. Old age was 
he main reason underlying this perspective. (4) 12 • 50% (2/16) ex- 
erienced fear, anxiety, or uneasiness about the endoscopic exam- 
nation per se. (5) Non-disclosure was observed in 12 • 50% (2/16) 
articipants. The patients’ first-degree relatives (spouse, offspring 
tc.) were informed of the screening results, but did not discuss 
he results with the patients themselves. 
For the 85 participants who received timely treatment after 
creening, the types of therapies they accepted are tabulated in 
able 3 . In patients with early-stage lesions, only about 1/4 re- 
eived endoscopic treatment, and the rest received radical surgery 
r combined radical surgery and radio-chemotherapy. Among the 
atients treated in secondary health care facilities, none received 
ndoscopic therapy, while the proportion of endoscopic therapy in 
ertiary health care facilities was 35 • 48%. For patients with lesions 
hich were not early-stage, no significant differences in types of 
herapy were found in secondary versus tertiary health care facili- 
ies. 
Regarding the reasons for choosing given health care facilities 
or treatment, 32 participants treated in secondary health care 
acilities and 46 treated in tertiary health care facilities partici- 
ated in our semi-structured interview and described their choices 
 Figure 2 ). 
The main reasons for choice of secondary health care facilities 
ere: (1) “Convenience”. 46 • 88% (15/32) chose secondary health 
are facilities based on close location, and convenience for relatives 
aking care of them during treatment/hospitalization. (2) “Medical 
xpenses”. 21 • 88% (7/32) believed secondary health care facilities 
ave lower treatment fees and a higher medical insurance reim- 
ursement rate as compared with tertiary health care facilities. (3) 
Expert effect”. 18 • 75% (6/32) reported that a secondary health care 
acility could invite experts from the prefecture- and province-level 
ospitals to provide medical service for local residents. 
The main reasons for choosing tertiary health care facilities 
ere: (1) “Social network”. 45 • 65% (21/46) reported that they 
new someone who could help arrange clinical treatment in 
refecture- or province-level hospitals. (2) “Quality of care”. 34 • 78% 
16/46) believed tertiary health care facilities provide better med- 
cal service. (3) “Family support”. 26 • 09% (12/46) chose a tertiary 
ospital because of advice or financial support from their offspring. 
Among the patients who received timely treatment, only 
0 • 26% (8/78) indicated that the decision was made based on the 
dvice of the screening team endoscopists, and 2 • 56% (2/78) con- 
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Table 1 
The characteristics of 133 individuals with malignant upper G.I. lesions detected at baseline screening of the ESECC 
trial in rural Hua County, China. 
Variable Timely treatment, N (%) No timely treatment, N (%) Total, N (%) 
N a 85 (63 • 91) 48 (36 • 09) 133 (100 • 00) 
Age 
45-54 1 (1 • 18) 5 (10 • 42) 6 (4 • 51) 
55-64 52 (61 • 18) 29 (60 • 42) 81 (60 • 90) 
65-69 32 (37 • 65) 14 (29 • 17) 46 (34 • 59) 
Gender 
Male 50 (58 • 82) 29 (60 • 42) 79 (59 • 40) 
Female 35 (41 • 18) 19 (39 • 58) 54 (40 • 60) 
Education 
Primary school or below 63 (74 • 12) 29 (60 • 42) 92 (69 • 17) 
Middle school or above 22 (25 • 88) 19 (39 • 58) 41 (30 • 83) 
Job type 
Official 0 (0 • 00) 1 (2 • 08) 1 (0 • 75) 
Farmer 85 (100 • 00) 47 (97 • 92) 132 (99 • 25) 
Annual per capita household income 
≤2000RMB 27 (31 • 76) 16 (33 • 33) 43 (32 • 33) 
> 2000RMB 26 (30 • 59) 20 (41 • 67) 46 (34 • 59) 
Unknown 32 (37 • 65) 12 (25 • 00) 44 (33 • 08) 
Marital status 
Married 75 (88 • 24) 43 (89 • 58) 118 (88 • 72) 
Unmarried 10 (11 • 76) 5 (10 • 42) 15 (11 • 28) 
Living arrangements 
Living alone or with spouse only 37 (43 • 53) 18 (37 • 50) 55 (41 • 35) 
Living with offspring 48 (56 • 47) 30 (62 • 50) 78 (58 • 65) 
Family history of esophageal cancer 
No 68 (80 • 00) 40 (83 • 33) 108 (81 • 20) 
Yes 17 (20 • 00) 8 (16 • 67) 25 (18 • 80) 
G.I. cancer-related symptoms b 
No 44 (51 • 76) 28 (58 • 33) 72 (54 • 14) 
Yes 41 (48 • 24) 20 (41 • 67) 61 (45 • 86) 
G.I.: gastrointestinal; ESECC: Endoscopic Screening for Esophageal Cancer in China. 
a Three participants whose treatment status was not confirmed were not included. 
b G.I. cancer-related symptoms included dysphagia, chest pain, heartburn/reflux, appetite change/indigestion, 
black stool, upper abdominal pain or weight loss. 
Table 2 
Correlation of tumor stage with treatment status in 133 patients with malignant upper G.I. lesions detected at baseline screening in the ESECC trial in rural 
Hua County, China. 
Lesions Timely treatment, N (%) No timely treatment, N (%) Adjusted OR (95%CI) c Risk differences(95%CI) d 
Total upper G.I. malignant lesions a 
Non-early-stage lesions 42 (93 • 33) 3 (6 • 67) Ref Ref 
Early-stage lesions 43 (48 • 86) 45 (51 • 14) 16 • 46 (4 • 62, 58 • 62) 0 • 45 (0 • 29, 0 • 56) 
Total b 85 (63 • 91) 48 (36 • 09) 
Esophagus 
Squamous cell carcinoma 32 (94 • 12) 2 (5 • 88) Ref Ref 
Severe dysplasia/carcinoma in situ 35 (46 • 05) 41 (53 • 95) 23 • 36 (4 • 97, 109 • 85) 0 • 48 (0 • 31, 0 • 60) 
Total 67 (60 • 91) 43 (39 • 09) 
Gastric cardia/Gastric non-cardia 
Adenocarcinoma 10 (90 • 91) 1 (9 • 09) Ref Ref 
Severe dysplasia/carcinoma in situ 8 (66 • 67) 4 (33 • 33) 5 • 46 (0 • 33, 89 • 25) 0 • 24 (-0 • 10, 0 • 53) 
Total 18 (78 • 26) 5 (21 • 74) 
G.I.: gastrointestinal; ESECC: Endoscopic Screening for Esophageal Cancer in China; OR: odd ratio; CI: confidence intervals; Ref: reference. 
a The early-stage lesions included severe dysplasia and carcinoma in situ, the non-early-stage lesions included esophageal squamous cell carcinoma, 
gastric cardia and gastric non-cardial adenocarcinoma. 
b Three participants whose treatment status was not confirmed were not included. 
c The OR was adjusted for age and gender. 




















ulted their village doctors before choosing a health care facility 
or treatment. 
iscussion 
Cancer screening has long been an important strategy for re- 
ucing the burden of cancer mortality. The efficacy of a screen- 
ng modality depends on identification and removal of cancer at 
n early stage. Timely and appropriate treatment for lesions de- 
ected with screening is therefore crucial to ensure the protective 
ffect of screening. However, in real-world screening practice de- 5 ay of treatment after screening is common, and this may lead to 
ower actual “effectiveness” of screening than the putative “effi- 
acy” of screening. Thus, effective management of individuals who 
re screening-positive is an important component in the screen- 
ng program. Considering the two common management strategies, 
he “screening & treatment” strategy may ensure that more people 
ill receive treatment, but a professional team with sufficient re- 
ources is needed to satisfactorily complete treatment. In contrast, 
he “screening & recommendation” strategy, which requires fewer 
esources and incurs fewer ethical problems has been widely used 
n China. Most EC screening programs in China have been con- 
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Table 3 
Treatment modalities used in 85 patients with malignant upper G.I. lesions detected at baseline screening in the ESECC trial in rural Hua County, China. 
Clinical 
therapy 
Level of health care facility, N (%) 




Early-stage lesions a 
Endoscopic therapy 0 (0 • 00) 11 (35 • 48) 11 (25 • 58) 0 • 36 (0 • 07, 0 • 53) 
Radical surgery/radical surgery combined with radio-chemotherapy 12 (100 • 00) 20 (64 • 52) 32 (74 • 42) -0 • 36 (-0 • 53, -0 • 07) 
Total 12 (100 • 00) 31 (100 • 00) 43 (100 • 00) 
Non-early-stage lesions a 
Radical surgery 17 (73 • 91) 15 (78 • 95) 32 (76 • 19) 0.05 (-0 • 21, 0 • 29) 
Radical surgery combined with radio-chemotherapy/radio-chemotherapy 6 (26 • 09) 4 (21 • 05) 10 (23 • 81) -0 • 05 (-0 • 29, 0 • 21) 
Total 23 (100 • 00) 19 (100 • 00) 42 (100 • 00) 
G.I.: gastrointestinal; ESECC: Endoscopic Screening for Esophageal Cancer in China; CI: confidence intervals. 
a Early-stage lesions included severe dysplasia and carcinoma in situ, non-early-stage lesions included esophageal squamous cell carcinoma, gastric cardia and gastric 
non-cardial adenocarcinoma. 
b The proportion of different treatment modalities in health care facilities of each level (column percentage), where secondary health care facilities served as a reference 
group. 
Figure 2. Factors influencing the choice of health care facilities in 78 upper G.I. cancer patients who were treated in a timely manner detected at baseline screening in 
ESECC trial, rural Hua County, China. 













































ucted in rural high-risk areas that are economically underdevel- 
ped. 8 No study has investigated whether screening-positive par- 
icipants received timely and appropriate treatment, and what fac- 
ors influenced their health-seeking behavior. This study, for the 
rst time has mapped out the real-world health-seeking behavior 
f screening-detected upper G.I. cancer patients from an area at 
igh-risk for EC in China based on a large population-level screen- 
ng trial. Our findings may provide evidence for formulating and 
ailoring management strategy for cancer screening in rural areas 
n China, and also provide guidance for screening in other similar 
ettings. 
In this study, we found that more than a third of patients 
ith malignant lesions which were detected in the initial screening 
ere not treated in a timely manner, and persons with early-stage 
ancer were more likely to delay treatment. By use of interviews, 
e identified the reasons for lack of timely treatment. First, low 
ealth awareness and socio-economic status were the main rea- 
ons which deterred 4 4 • 4 4% (16/36) patients from seeking further 
iagnosis and treatment. Second, 30 • 56% (11/36) of the untreated 
atients had undergone an endoscopic re-examination as a diag- 
ostic test, but no abnormality was detected, so the screening re- 
ult was considered to be a false positive. This inconsistency was 
argely due to the fact that no iodine staining was used in the 6 iagnostic test. Endoscopic examination with Lugol’s iodine stain- 
ng has high sensitivity for detection of early-stage lesions in the 
sophagus, and was adopted in the ESECC trial. 17 But this stain- 
ng procedure has not been routinely adopted for endoscopy in 
eneral clinical settings, and the sensitivity of routine white light 
ndoscopy for detecting early-stage lesions is as low as 11 • 1%. 18 
sophageal lesions, and in particular early-stage esophageal lesions 
re therefore likely to be missed. In addition, without a full evalua- 
ion and understanding of screening results, physicians performing 
ndoscopic re-examination would not have specific expectations 
egarding the risk in a given patient prior to the endoscopy, which 
ould further limit the application of more sensitive methods (e.g. 
ugol’s iodine staining, 17 narrow-band imaging, 19 etc.) and targeted 
iopsy. Third, 25% (9/36) patients were not referred for further en- 
oscopic re-examination or clinical treatment by gastroenterolo- 
ists; and oral medication or regular surveillance alone was sug- 
ested by clinicians who were consulted. This reflected the doctors’ 
ack of awareness of the significance of screening results and basic 
nowledge of diagnosis and treatment of early upper G.I. cancer. 
For patients with early lesions such as severe dysplasia and 
arcinoma in situ or intramucosal carcinomas, endoscopic therapy 
as been recommended as a less-invasive alternative to traditional 
urgery. 20 In China, most upper G.I. cancer screening projects in 







































































































igh-risk areas were undertaken in a secondary health care facil- 
ty, that is, the county-level hospital. 16 Currently, the health ser- 
ice capacity of secondary facilities in most areas of China do not 
eet the requirements for independent endoscopic treatment. Pa- 
ients who choose these facilities therefore lose the opportunity to 
eceive endoscopic therapy. In this study, we found that patients 
ere strongly influenced by subjective factors in choosing facili- 
ies for clinical treatment, and often gave priority to factors not 
irectly related to disease such as “Convenience”, “Social network”, 
r “Medical expense” for choice of a treatment facility, rather than 
asing decisions on quality and capacity of the medical services. 
e speculate the main reasons for this are likely related to the 
act that most of these patients had a low level of education to- 
ether with poor health awareness. 21 Many of these individuals 
ere hardly able to understand the disease with which they pre- 
ented, the differences between various clinical treatments, and 
he suggestions made by the screening team professionals. This led 
o poor accessibility of high-quality medical resources and health 
ervices suitable for these persons. 
Based on the findings of this study, we suggest adopting a “co- 
rdinated, system-based” patient management strategy when de- 
igning an upper G.I. cancer screening project for use in a rural 
opulation to ensure timely and appropriate clinical treatment of 
alignant lesions detected by screening. First, before a screening 
rogram is initiated, a medical alliance comprising general and 
ancer hospitals at different levels in a given local area should be 
stablished, so that screening results can be mutually recognized 
mong members of the alliance. Standardized training for endo- 
copists and gastroenterologists should be routinely conducted to 
mprove their understanding of the screening procedure and crite- 
ia, and the guidelines for the diagnosis and treatment of early up- 
er G.I. cancer. For example, techniques with higher sensitivity for 
etection of early lesions should be used during the endoscopic re- 
xamination. Through close cooperation among alliance members, 
 “fast track” referral system for individuals who are screening- 
ositive should be established where patients can get professional 
dvice and standardized referral to an appropriate health care fa- 
ility. 
Second, cancer screening programs may incorporate a primary 
are network for more integrated management of cancer patients. 
illage doctors have played an irreplaceable role in rural health 
are in China. They are often residents of the villages they serve 
nd well respected by local residents. By introducing village doc- 
ors into screening programs, the barriers in communication with 
ural residents would be diminished, facilitating supervision and 
uidance for the health-seeking process, hence improving manage- 
ent of cancers detected by screening. 
In order to verify the performance of a proposed method of 
anagement after screening, a small alliance was established in 
he re-examination phase of the ESECC trial which consisted of a 
econdary local health care facility, Hua County People’s Hospital, 
nd Anyang Cancer Hospital which is a tertiary health care facility, 
here 2/3 of cases identified at baseline screening received timely 
reatment. A referral arrangement was made to help patients with 
ubsequent endoscopic re-examination and clinical treatment. As 
 result, the proportion of patients with malignant lesions who 
eceived timely treatment increased from 63 • 91% at baseline to 
1 • 48%, and the proportion of endoscopic therapy used in cases 
hich were diagnosed early increased from 25 • 58% at baseline to 
1 • 67%. 
There are also limitations in this study that should be noted. 
his was a single center study, and our findings should therefore 
e interpreted with caution when applied in other areas in China 
nd in other countries. In addition, since information about health- 
eeking behavior was collected via retrospective interviews, recall 
ias and reporting bias may exist where the respondents could not 7 ccurately recall the health-seeking experiences, or intentionally 
xaggerated or concealed the true information. 
This study has described for the first time the health-seeking 
rajectory of screening-detected upper G.I. cancer patients and the 
ain barriers to access of timely and appropriate clinical treat- 
ent in rural China in areas of high ESCC incidence. Results of this 
tudy will provide a fundamental basis for the efficacy and cost- 
ffectiveness evaluation in the ESECC trial in the future. In addi- 
ion, establishing a regional medical alliance and involving primary 
are networks will help overcome identified barriers and facilitate 
he management of patients with cancer detected by screening in 
hese programs. It is expected that this will improve the efficiency 
f diagnostic testing and clinical treatment after the initial screen- 
ng. This study will inform planning of screening for upper G.I. can- 
er in rural China and other settings with similar social-economic 
onditions. 
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